JANX

$0.00

(

+0.00%

)
Quote details

stock

Janux Therapeutics Inc

NASDAQ | JANX

23.46

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 17, 2025)

$1.41B

Market Cap

-

P/E Ratio

-1.81

EPS

$71.70

52 Week High

$21.97

52 Week Low

HEALTHCARE

Sector

JANX Chart

Recent Chart
Price Action

JANX Technicals

Tags:

JANX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $8.5M
Total Revenue $11M
Cost Of Revenue $2.1M
Costof Goods And Services Sold $2.1M
Operating Income -$99M
Selling General And Administrative $41M
Research And Development $68M
Operating Expenses $107M
Investment Income Net -
Net Interest Income $30M
Interest Income $30M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.1M
Income Before Tax -$69M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$69M
Comprehensive Income Net Of Tax -
Ebit -$101M
Ebitda -$99M
Net Income -$69M

Revenue & Profitability

Earnings Performance

JANX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.1B
Total Current Assets $1B
Cash And Cash Equivalents At Carrying Value $431M
Cash And Short Term Investments $431M
Inventory -
Current Net Receivables $5.4M
Total Non Current Assets $28M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $595M
Other Current Assets $3.1M
Other Non Current Assets -
Total Liabilities $39M
Total Current Liabilities $17M
Current Accounts Payable $4M
Deferred Revenue -
Current Debt -
Short Term Debt $3.5M
Total Non Current Liabilities $21M
Capital Lease Obligations $23M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $23M
Other Current Liabilities $9.9M
Other Non Current Liabilities -
Total Shareholder Equity $1B
Treasury Stock -
Retained Earnings -$238M
Common Stock $59K
Common Stock Shares Outstanding $54M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$44M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.1M
Capital Expenditures $359K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$258M
Cashflow From Financing $713M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$69M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $8.5M
Total Revenue $11M
Cost Of Revenue $2.1M
Costof Goods And Services Sold $2.1M
Operating Income -$99M
Selling General And Administrative $41M
Research And Development $68M
Operating Expenses $107M
Investment Income Net -
Net Interest Income $30M
Interest Income $30M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.1M
Income Before Tax -$69M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$69M
Comprehensive Income Net Of Tax -
Ebit -$101M
Ebitda -$99M
Net Income -$69M

JANX News

JANX Profile

Janux Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Janux Therapeutics, Inc. is a biopharmaceutical company focused on innovating cancer therapies through its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology. Based in La Jolla, California, Janux is dedicated to advancing its pipeline of cancer immunotherapies designed to selectively target and eliminate tumor cells, thereby improving patient outcomes. The company's strategic approach positions it to address significant unmet medical needs within oncology, leveraging its expertise in T cell biology and tumor activation mechanisms.

ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
QBTS
+18.75%
$22.54
NIO
+6.05%
$7.44
SPRC
+142.93%
$4.47
GRAB
-3.48%
$6.10
AAL
+0.56%
$12.48
TSLA
+1.00%
$425.86
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
RGTI
+9.94%
$21.99
SOFI
-1.02%
$27.14
TPIC
-45.91%
$0.12
ADAP
-1.22%
$0.08
PLTR
-1.13%
$168.33
DNN
+1.60%
$2.54
AXDX
-61.36%
$0.03
BBD
+3.11%
$3.31
BMNR
+2.03%
$57.07
INTC
-1.46%
$24.90
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
KDLY
-4.66%
$1.43
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
IONQ
+5.10%
$65.44
NAKA
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.98%
$92.95
RIOT
+0.57%
$17.62
AMZN
-1.03%
$231.62
AIRE
-1.57%
$1.25
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
ABEV
0.00%
$2.36
LDI
+2.70%
$4.55
BINI
-6.96%
$0.06
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
INFY
+3.63%
$17.68
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
JD
+1.52%
$35.24
ATYR
-5.09%
$1.02
GPUS
+6.65%
$0.41
FAAS
-6.04%
$0.09
ITUB
+1.82%
$7.27
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BABA
+2.44%
$166.17
KEY
+0.42%
$18.71
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
IONZ
-10.28%
$4.80
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
GDXD
+1.63%
$1.24
RXRX
-2.68%
$4.71
RAYA
-4.69%
$0.04
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
QBTS
+18.75%
$22.54
NIO
+6.05%
$7.44
SPRC
+142.93%
$4.47
GRAB
-3.48%
$6.10
AAL
+0.56%
$12.48
TSLA
+1.00%
$425.86
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
RGTI
+9.94%
$21.99
SOFI
-1.02%
$27.14
TPIC
-45.91%
$0.12
ADAP
-1.22%
$0.08
PLTR
-1.13%
$168.33
DNN
+1.60%
$2.54
AXDX
-61.36%
$0.03
BBD
+3.11%
$3.31
BMNR
+2.03%
$57.07
INTC
-1.46%
$24.90
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
KDLY
-4.66%
$1.43
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
IONQ
+5.10%
$65.44
NAKA
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.98%
$92.95
RIOT
+0.57%
$17.62
AMZN
-1.03%
$231.62
AIRE
-1.57%
$1.25
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
ABEV
0.00%
$2.36
LDI
+2.70%
$4.55
BINI
-6.96%
$0.06
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
INFY
+3.63%
$17.68
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
JD
+1.52%
$35.24
ATYR
-5.09%
$1.02
GPUS
+6.65%
$0.41
FAAS
-6.04%
$0.09
ITUB
+1.82%
$7.27
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BABA
+2.44%
$166.17
KEY
+0.42%
$18.71
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
IONZ
-10.28%
$4.80
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
GDXD
+1.63%
$1.24
RXRX
-2.68%
$4.71
RAYA
-4.69%
$0.04
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.